SummaryRMgm-626
|
Successful modification | The parasite was generated by the genetic modification |
The mutant contains the following genetic modification(s) | Gene disruption |
Reference (PubMed-PMID number) |
Reference 1 (PMID number) : 21752110 |
MR4 number | |
top of page | |
Parent parasite used to introduce the genetic modification | |
Rodent Malaria Parasite | P. berghei |
Parent strain/line | P. berghei NK65 |
Name parent line/clone | Not applicable |
Other information parent line | |
top of page | |
The mutant parasite was generated by | |
Name PI/Researcher | B. Boisson; R. Ménard; P. Baldacci |
Name Group/Department | Biologie et Génétique du Paludisme |
Name Institute | Institut Pasteur |
City | Paris |
Country | France |
top of page | |
Name of the mutant parasite | |
RMgm number | RMgm-626 |
Principal name | NPT1-Δ |
Alternative name | |
Standardized name | |
Is the mutant parasite cloned after genetic modification | Yes |
top of page | |
Phenotype | |
Asexual blood stage | Not different from wild type |
Gametocyte/Gamete | Strongly reduced gametocyte production. The few gametocytes present show an aberrant morphology. These aberrant forms are unable to fertilize and produce ookinetes |
Fertilization and ookinete | No ookinete production |
Oocyst | No ookinete and oocyst production |
Sporozoite | No ookinete, oocyst and sporozoite production |
Liver stage | Not tested |
Additional remarks phenotype | Mutant/mutation The number of gametocytes in parasites lacking expression of NPT1 is 90-95% reduced as demonstrated by FACS counting of mature gametocytes. For FACS counting of male and female gametocytes the npt1 gene was disrupted in the reporter line Fluofrmg that expresses RFP and GFP under the control of female- and male-specific promoters (see mutant RMgm-629). In the same study a mutant has been generated in which the npt1 gene was partially deleted (NPT1-I). These parasites show an unexpected presence of a long ‘chimeric’ transcript encompassing the entire disrupted locus. Since no antibodies against NPT1 could be generated, it was not possible to analyse whether these transcripts would give rise to a (truncated) NPT1 protein. This mutant showed however the same phenotype as the phenotype described here for the mutant lacking the complete npt1 gene. In order to verify that the phenotype of mutant parasites was due solely to the genetic modifications introduced in the npt1 locus and not to other mutations that may have occurred during the selection of the parasites or to an effect on neighbouring genes, the NPT1-I strain has been complemented with an intact npt1 gene . To this end, a plasmid, c-npt1-gfp, containing 500bp of the 5’UTR, the entire ORF and 1000bp of the 3’UTR of npt1, together with gfp driven from the hsp70 promoter was inserted by single cross-over into the npt1-I locus. This insertion generated a full-length npt1 ORF driven by the native promoter and 1000bp of the endogenous 3`UTR. Phenotype analyses of the complemented parasites showed restoration of normal (wild type) gametocyte production. |
top of page | |||||||||||||||||||||||||
Details of the target gene | |||||||||||||||||||||||||
Gene Model of Rodent Parasite | PBANKA_0208300 | ||||||||||||||||||||||||
Gene Model P. falciparum ortholog | PF3D7_0104800 | ||||||||||||||||||||||||
Gene product | novel putative transporter 1, putative | ||||||||||||||||||||||||
Gene product: Alternative name | Novel Putative Transporter, NPT1 | ||||||||||||||||||||||||
top of page | |||||||||||||||||||||||||
Details of the genetic modification | |||||||||||||||||||||||||
Inducable system used | No | ||||||||||||||||||||||||
Additional remarks inducable system | |||||||||||||||||||||||||
Type of plasmid/construct used | Plasmid double cross-over | ||||||||||||||||||||||||
PlasmoGEM (Sanger) construct/vector used | No | ||||||||||||||||||||||||
Modified PlasmoGEM construct/vector used | No | ||||||||||||||||||||||||
Plasmid/construct map | |||||||||||||||||||||||||
Plasmid/construct sequence | |||||||||||||||||||||||||
Restriction sites to linearize plasmid | |||||||||||||||||||||||||
Partial or complete disruption of the gene | Complete | ||||||||||||||||||||||||
Additional remarks partial/complete disruption | |||||||||||||||||||||||||
Selectable marker used to select the mutant parasite | hdhfr | ||||||||||||||||||||||||
Promoter of the selectable marker | pbdhfr | ||||||||||||||||||||||||
Selection (positive) procedure | pyrimethamine | ||||||||||||||||||||||||
Selection (negative) procedure | No | ||||||||||||||||||||||||
Additional remarks genetic modification | |||||||||||||||||||||||||
Additional remarks selection procedure | |||||||||||||||||||||||||
Primer information: Primers used for amplification of the target sequences
![]() Primer information: Primers used for amplification of the target sequences
![]()
| |||||||||||||||||||||||||
top of page |